tiprankstipranks
NeuroSense reports positive preliminary results in Parkinson’s study
The Fly

NeuroSense reports positive preliminary results in Parkinson’s study

NeuroSense announced positive preliminary results from a novel biomarker study conducted to evaluate the potential of NeuroSense’s combination platform therapy for the treatment of Parkinson’s disease – PD -. This study compared blood samples from 30 healthy individuals to 30 people living with PD by utilizing neuronal derived exosomes to identify modulations in PD-associated biomarkers, including AG02. AGO2 – Argonaute 2 -, the catalytic subunit of the protein complex responsible for RNA-induced silencing, was shown to be critical to the regulation of alpha-synuclein accumulation in dopaminergic neurons of the substantia nigra pars compacta, the region of the brain that is responsible for motor control. The dysregulation of alphaSyn through dysfunction of AGO2 can have detrimental effects in the brain, which can lead to PD. In the PD biomarker study, NeuroSense observed a statistically significant decrease in levels of AGO2 in newly diagnosed PD patients when compared to the healthy control group. There were no significant changes observed in AGO2 levels of more advanced stage PD patients, indicating this trend could be related to disease onset. In the PD biomarker study NeuroSense observed a change in levels of LC3, which decreased in newly diagnosed PD patients, suggesting an impairment in cellular recycling processes. Other biomarkers that were measured, including some PD-specific markers, did not reveal trends and may be revisited in future studies.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on NRSN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles